SWISSMED Bioflèx
Natural health product licensed in Canada
- Other names
- SWISSMED Bioflèx Tablet
- Licence holder
- NuEra Nutraceutical Inc.
- NPN or DIN-HM
- 80089954
- Status
- Active licence
- Licence date
- 7 January 2019
- Revision date
- 12 August 2020
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Boswellia serrata Source : Gum oleoresin Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 1,000 milligramme Potency : 20 % 3-Acetyl-11-keto-beta-boswellic acid | 100 milligramme | Not calculated |
| Membrane de coquille d'oeuf de poule partiellement hydrolysée Source : Gallus gallus - Coquille d'oeuf | 450 milligramme | Not calculated |
Non-medicinal ingredients
Croscarmellose de sodium, Acide stéarique, Dioxyde de titane, Hydroxypropylméthylcellulose, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Comprimé | 1 day |
Uses authorised in Canada
Helps reduce pain associated with osteoarthritis. Helps to reduce stiffness associated with osteoarthritis. Helps to relieve joint pain associated with osteoarthritis. Helps to relieve pain associated with osteoarthritis of the knee. Helps to reduce joint pain associated with osteoarthritis. Helps to reduce stiffness associated with osteoarthritis. Helps to relieve joint pain and stiffness associated with osteoarthritis. Helps to reduce blood C reactive protein levels, a clinical marker of inflammation. Starts to help reduce pain at 5 days.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity (e.g. allergy) has been known to occur; in which case, discontinue use. Some people may experience mild gastrointestinal disturbances such as diarrhoea, abdominal pain, heartburn, nausea and vomiting; in which case, discontinue use.
- Précautions et mises en garde
Consult a health care professional prior to use if you are pregnant or breastfeeding have a serious health condition or are taking prescription medications. Consult a health care practitioner if symptoms worsen. Consult a healthcare practitioner prior to use if you are allergic to eggs.
Source
Official Health Canada record, licence 80089954
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2020. Photograph the packaging to check whether it has changed. Photograph the packaging